Literature DB >> 21210219

Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias.

Ilya Bezprozvanny1.   

Abstract

Huntington's disease (HD) and spinocerebellar ataxias (SCAs) are autosomal-dominant neurodegenerative disorders. HD is caused by polyglutamine (polyQ) expansion in the amino-terminal region of a protein huntingtin (Htt) and primarily affects medium spiny striatal neurons (MSN). Many SCAs are caused by polyQ-expansion in ataxin proteins and primarily affect cerebellar Purkinje cells. The reasons for neuronal dysfunction and death in HD and SCAs remain poorly understood and no cure is available for the patients. Our laboratory discovered that mutant huntingtin, ataxin-2 and ataxin-3 proteins specifically bind to the carboxy-terminal region of the type 1 inositol 1,4,5-trisphosphate receptor (IP(3)R1), an intracellular Ca(2+) release channel. Moreover, we found that association of mutant huntingtin or ataxins with IP(3)R1 causes sensitization of IP(3)R1 to activation by IP(3) in planar lipid bilayers and in neuronal cells. These results suggested that deranged neuronal Ca(2+) signaling might play an important role in pathogenesis of HD, SCA2 and SCA3. In support of this idea, we demonstrated a connection between abnormal Ca(2+) signaling and neuronal cell death in experiments with HD, SCA2 and SCA3 transgenic mouse models. Additional data in the literature indicate that abnormal neuronal Ca(2+) signaling may also play an important role in pathogenesis of SCAl, SCA5, SCA6, SCA14 and SCA15/16. Based on these results I propose that IP(3)R and other Ca(2+) signaling proteins should be considered as potential therapeutic targets for treatment of HD and SCAs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21210219      PMCID: PMC3094593          DOI: 10.1007/s11064-010-0393-y

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  146 in total

1.  Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening.

Authors:  Y Nagai; T Tucker; H Ren; D J Kenan; B S Henderson; J D Keene; W J Strittmatter; J R Burke
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

2.  Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models.

Authors:  Dagmar E Ehrnhoefer; Martin Duennwald; Phoebe Markovic; Jennifer L Wacker; Sabine Engemann; Margaret Roark; Justin Legleiter; J Lawrence Marsh; Leslie M Thompson; Susan Lindquist; Paul J Muchowski; Erich E Wanker
Journal:  Hum Mol Genet       Date:  2006-08-07       Impact factor: 6.150

Review 3.  Neuronal calcium signaling.

Authors:  M J Berridge
Journal:  Neuron       Date:  1998-07       Impact factor: 17.173

4.  Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95.

Authors:  Y Sun; A Savanenin; P H Reddy; Y F Liu
Journal:  J Biol Chem       Date:  2001-04-23       Impact factor: 5.157

5.  Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia.

Authors:  A J Cross; T J Crow; J A Johnson; J M Dawson; T J Peters
Journal:  J Neurol Sci       Date:  1985-12       Impact factor: 3.181

6.  Widespread expression of inositol 1,4,5-trisphosphate receptor type 1 gene (Insp3r1) in the mouse central nervous system.

Authors:  T Furuichi; D Simon-Chazottes; I Fujino; N Yamada; M Hasegawa; A Miyawaki; S Yoshikawa; J L Guénet; K Mikoshiba
Journal:  Receptors Channels       Date:  1993

Review 7.  Huntingtin: alive and well and working in middle management.

Authors:  Marcy E MacDonald
Journal:  Sci STKE       Date:  2003-11-04

8.  Riluzole in Huntington's disease: a 3-year, randomized controlled study.

Authors:  G Bernhard Landwehrmeyer; Bruno Dubois; Justo Garcia de Yébenes; Berry Kremer; Wilhelm Gaus; Peter H Kraus; Horst Przuntek; Michel Dib; Adam Doble; Wilhelm Fischer; Albert C Ludolph
Journal:  Ann Neurol       Date:  2007-09       Impact factor: 10.422

9.  Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses.

Authors:  Sofia Papadia; Francesc X Soriano; Frédéric Léveillé; Marc-Andre Martel; Kelly A Dakin; Henrik H Hansen; Angela Kaindl; Marco Sifringer; Jill Fowler; Vanya Stefovska; Grahame McKenzie; Marie Craigon; Roderick Corriveau; Peter Ghazal; Karen Horsburgh; Bruce A Yankner; David J A Wyllie; Chrysanthy Ikonomidou; Giles E Hardingham
Journal:  Nat Neurosci       Date:  2008-03-23       Impact factor: 24.884

10.  Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1.

Authors:  Robert Goold; Michael Hubank; Abigail Hunt; Janice Holton; Rajesh P Menon; Tamas Revesz; Massimo Pandolfo; Antoni Matilla-Dueñas
Journal:  Hum Mol Genet       Date:  2007-06-28       Impact factor: 6.150

View more
  37 in total

1.  Further evidence for the role of IP 3R 1 in regulating subsynaptic gene expression and neuromuscular transmission.

Authors:  Haipeng Zhu; Christopher M Gomez
Journal:  Channels (Austin)       Date:  2012-01-01       Impact factor: 2.581

2.  RNF170 protein, an endoplasmic reticulum membrane ubiquitin ligase, mediates inositol 1,4,5-trisphosphate receptor ubiquitination and degradation.

Authors:  Justine P Lu; Yuan Wang; Danielle A Sliter; Margaret M P Pearce; Richard J H Wojcikiewicz
Journal:  J Biol Chem       Date:  2011-05-24       Impact factor: 5.157

Review 3.  Disturbed calcium signaling in spinocerebellar ataxias and Alzheimer's disease.

Authors:  Polina Egorova; Elena Popugaeva; Ilya Bezprozvanny
Journal:  Semin Cell Dev Biol       Date:  2015-04-04       Impact factor: 7.727

4.  Familial Alzheimer's disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis.

Authors:  Diego Sepulveda-Falla; Alvaro Barrera-Ocampo; Christian Hagel; Anne Korwitz; Maria Fernanda Vinueza-Veloz; Kuikui Zhou; Martijn Schonewille; Haibo Zhou; Luis Velazquez-Perez; Roberto Rodriguez-Labrada; Andres Villegas; Isidro Ferrer; Francisco Lopera; Thomas Langer; Chris I De Zeeuw; Markus Glatzel
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

5.  A novel gain-of-function mutation in the ITPR1 suppressor domain causes spinocerebellar ataxia with altered Ca2+ signal patterns.

Authors:  Jillian P Casey; Taisei Hirouchi; Chihiro Hisatsune; Bryan Lynch; Raymond Murphy; Aimee M Dunne; Akitoshi Miyamoto; Sean Ennis; Nick van der Spek; Bronagh O'Hici; Katsuhiko Mikoshiba; Sally Ann Lynch
Journal:  J Neurol       Date:  2017-06-15       Impact factor: 4.849

6.  Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals.

Authors:  Haipeng Zhu; Bula J Bhattacharyya; Hong Lin; Christopher M Gomez
Journal:  J Neurosci       Date:  2011-10-26       Impact factor: 6.167

7.  In vivo analysis of cerebellar Purkinje cell activity in SCA2 transgenic mouse model.

Authors:  Polina A Egorova; Olga A Zakharova; Olga L Vlasova; Ilya B Bezprozvanny
Journal:  J Neurophysiol       Date:  2016-03-16       Impact factor: 2.714

Review 8.  Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease).

Authors:  Veronica F Colomer Gould
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

9.  A Point Mutation in the Ubiquitin Ligase RNF170 That Causes Autosomal Dominant Sensory Ataxia Destabilizes the Protein and Impairs Inositol 1,4,5-Trisphosphate Receptor-mediated Ca2+ Signaling.

Authors:  Forrest A Wright; Justine P Lu; Danielle A Sliter; Nicolas Dupré; Guy A Rouleau; Richard J H Wojcikiewicz
Journal:  J Biol Chem       Date:  2015-04-16       Impact factor: 5.157

10.  Progressive impairment of cerebellar mGluR signalling and its therapeutic potential for cerebellar ataxia in spinocerebellar ataxia type 1 model mice.

Authors:  Anton N Shuvaev; Nobutake Hosoi; Yamato Sato; Dai Yanagihara; Hirokazu Hirai
Journal:  J Physiol       Date:  2016-09-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.